Therapeutic interventions for HIV infection and chronic viral hepatitis

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Cooper, Curtis L ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ERYTHROPOIETIN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CYTOPENIA; DRUG ALCOHOL INTERACTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FEVER; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; IMMUNE RESPONSE; LACTIC ACIDOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; LYMPHOCYTE COUNT; MENTAL DISEASE; PANCREATITIS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SUBSTANCE ABUSE; T LYMPHOCYTE; TRANSAMINITIS; VIREMIA; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS LOAD;

ALCOHOL DRINKING; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER;

EID: 20844441454     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429499     Document Type: Review

References (50)

1. Stubble L, Soriano V, Antunes F. Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients: prevalence and prognostic value [abstract 22261]. In: Conference record of the 12th World AIDS Conference (Geneva). Stockholm: International AIDS Society, 1998:314.
2. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74:212-20.
3. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997; 11:F59-65.
4. Cooper CL, Chen Y, Garber GE, Cameron DW. Perturbation of HCV RNA levels in plasma after suppressive HAART in HIV-HCV co-infected subjects [abstract H-1736]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:279.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
6. Neau D, Trimoulet P, Winnock M, et al. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS 2001; 15:1736-8.
7. Trimoulet P, Neau D, Le Bail B, et al. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol 2002; 67:143-51.
8. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16:1915-23.
9. Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001; 33:1579-85.
10. Aceti A, Pasquazzi C, Zechini B. Alanine aminotransferase decrease in HIV-hepatitis C virus co-infected patients responding to antiretroviral therapy. AIDS 2003; 17:2141-2.
11. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.
12. Cooper C, LaRoche A, Kane M, Conto-Cohoon M, Lee C, Garber GE. Evaluation of the benefits of HAART in HIV-HCV co-infected subjects [abstract H-826]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobials and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:309.
13. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12:2289-93.
14. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000; 31:1234-9.
15. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-1.
16. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1803-4.
17. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995; 90:1433-6.
18. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-63.
19. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998; 27:1321-2.
20. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
21. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29:41-8.
22. Bernstein B, King M, Cernohous P, Moseley J, Sun E. Treatment of HIV+ subjects co-infected with hepatitis B or C: week 60 safety and efficacy comparison of lopinavir/ritonavir vs. nelfinavir from a phase III blinded randomized clinical trial [abstract P228]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Paris: European AIDS Clinical Society, 2001:151.
23. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-9.
24. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
25. Fischl MA, Young B, Watkins M, et al. Direct study: a multicenter, open-label, 24-wk pilot study with a 24-wk extension to evaluate the safety, tolerability and efficacy of indinavir-ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals [abstract I-1923]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:344.
26. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34:1259-63.
27. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17:691-8.
28. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
29. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
30. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562-8.
31. Da Silva LC, Pinho JR, Sitnik R, Da Fonseca LE, Carrilho FJ. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 2001; 36:476-85.
32. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-6.
33. Cooper D, Coakley DF, Sayre J, et al. Anti-hepatitis B virus (HBV) activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV co-infected patients [abstract 6015]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Vol. II. Stockholm: International AIDS Society, 2002:82.
34. Bochet M, Tubiana R, Benhamou Y, et al. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV [abstract 675-M]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 299.
35. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694-7.
36. Neau D, Trimoulet P, Winnock M, et al. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 2003; 36:1564-71.
37. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15:2149-55.
38. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
39. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
40. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-8.
41. Perronne C, Carrat F, Bani-Sadr F, et al. Final results of ANRS HCO2-RIBAVIC: a randomized controlled trial of pegylated-interferon-α-2b plus ribavirin vs. interferon-α-2b plus ribavirin for the initial treatment of chronic hepatitis in HIV co-infected patients [abstract 117LB]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004:119.
42. Hammoud G, Li J, Vega K, et al. Poor tolerability to high dose peg interferon and ribavirin in HIV/HCV coinfected patients: initial results from a randomized multicenter trial [abstract 347]. In: Program and abstracts of the 54th annual meeting of the American Association for the Study of Liver Diseases (Boston). Alexandria, VA: American Association for the Study of Liver Diseases, 2003:327A.
43. Emilie D, Burgard M, Lascoux-Combe C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001; 15:1435-7.
44. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357:196-7.
45. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299-306.
46. Di Bisceglie AM, Dienstag J, Bankovsky H, et al. Serum alpha-fetoprotein (AFP) levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: results from the HALT-C trial [abstract 567). In: Program and abstracts of the 54th annual meeting of the American Association for the Study of Liver Diseases (Boston). Alexandria, VA: American Association for the Study of Liver Diseases, 2003:439A.
47. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
48. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36:242-52.
49. Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002; 9:288-94.
50. Miguez MJ, Shor-Posner G, Morales G, Rodriguez A, Burbano X. HIV treatment in drug abusers: impact of alcohol use. Addict Biol 2003; 8: 33-7.